DM1 is a rare or orphan neuromuscular disease that affects more than one million people worldwide. As a result of more than 10 years of research on this disease, and in collaboration with prestigious research centers, MYOGEM succeeded in having its project “New food for special medical purposes for the nutritional management of Myotonic Dystrophy type 1” awarded by the European Commission under the Horizon 2020 research program, SME Instrument Phase 1, with two Seals of Excellence and subsequent funding that enables the launch of the clinical study of the MYODM food supplement.
The clinical study is led by Dr. Roberto Fernández Torrón and is being conducted by the Neurology Department at Donostia University Hospital, with the collaboration of the CRO MIAKER Developments S.L. Recruitment of adult volunteer patients diagnosed with DM1 has already begun. For more information, consult the clinicaltrials.gov database, trial code NCT04634682.
